Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Role of the Blood-Brain Barrier in Multiple Sclerosis.
The history of the oxazaphosphorine cytostatics.
Multiparametric MRI correlates of sensorimotor function in the spinal cord in multiple sclerosis.
Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results.
Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats.
Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord.
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
CD137 ligand activated microglia induces oligodendrocyte apoptosis via reactive oxygen species.
Lipocalin 2 is present in the EAE brain and is modulated by natalizumab.
Predictors of quality of life among multiple sclerosis patients: a comprehensive analysis.
Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with MS.
Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
Disease-modifying treatments for progressive multiple sclerosis.
Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.
Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose.
Gas6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination.
Fingolimod-A sphingosine-like molecule inhibits vesicle mobility and secretion in astrocytes.
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Cyclophosphamide
Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome.

Pages